Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now X
PharMerica Corporation (PMC)
Q4 2008 Earnings Call
February 6, 2009 10:00 am ET
Teri Hartlage – Vice President of Finance
Greg Weishar – Chief Executive Officer
Mike Culotta – Chief Financial Officer
Berard Tomassetti – Senior Vice President and Chief Accounting Officer
Glen Santangelo – Credit Suisse
Brendan Strong – Barclays Capital
Frank Morgan – RBC Capital Markets
Albert Rice – Soleil Securities
Constantine Davides – JMP Securities
Eric Gommel – Stifel Nicolaus
Robert Willoughby – Banc of America
Mike Petusky – Noble Research
Previous Statements by PMC
» PharMerica Corporation Q3 2008 Earnings Call Transcript
» PharMerica Corporation Q2 2008 Earnings Call Transcript
» PharMerica Corporation Q1 2008 Earnings Call Transcript
Good morning and thank you for joining us for the 2008 fourth quarter and year-end conference call for PharMerica Corporation. On the call with me today are Greg Weishar, Chief Executive Officer, Mike Culotta, Executive Vice President and Chief Financial Officer, and Berard Tomassetti, Senior Vice President and Chief Accounting Officer.
Before beginning our remarks regarding the fourth quarter and year-end results, I would like to make a cautionary statement. During the call today, we will make forward-looking statements about our business prospects and financial expectations. We want to remind you that there are many risks and uncertainties that could cause our actual results to differ materially from our current expectations.
In addition to the risks and uncertainties discussed in yesterday's press release and in the comments made during this conference call, more detailed information about additional risks and uncertainties may be found in our SEC filings, including our annual report on Form 10-K. Copies of these documents may be obtained from the SEC or by visiting the Investor Relations section of our website. PharMerica assumes no obligation to update these matters discussed on the call.
During this call, we will be referring to non-GAAP financial measures. These non-GAAP measures are not prepared in accordance with generally accepted accounting principles. A reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measures is available on our fourth quarter and year end 2008 financial results press release. We have made available to you our press release and our 10-K filed with the SEC. In addition, this webcast will be on our website along with the transcript from this call.
I would now like to turn the presentation over to Greg.
Welcome everyone. As always, we are pleased to have the opportunity to discuss our company's results today, and we thank you for your attendance. Before I get started with the financial highlights, let me remind you that from a comparative financial standpoint the combined businesses of KPS and PharMerica LTC were merged on July 31, 2007. Therefore, the results for the year ending December 31, 2007, represent the results of operations and cash flows of KPS for those full 12-month periods and PharMerica LTC effective August 1, 2007.
Yesterday evening, we released our fourth quarter and year-end results and we filed our 10-K. The diluted earnings per share for the year were $0.17 and our diluted loss per share was $0.18 for the quarter. Integration, merger-related costs, and other charges represented $8.9 million or $0.20 diluted loss per share for the quarter and represented $26.7 million or $0.53 diluted loss per share for the fiscal year. We took an impairment charge for intangible assets of $14.8 million or $0.30 diluted loss per share for the fiscal year and the quarter. Excluding the integration, merger-related costs and other charges, the impairment charge, and the effect of a favorable tax ruling, our diluted earnings per share totaled $0.26 for the quarter and $1.00 for the year. Our total revenues were $480 million during the quarter, and we dispensed approximately 10 million prescriptions in that period.
Looking at EBITDA, our adjusted EBITDA was $23.9 million for the quarter, giving us a 5% adjusted EBITDA margin. Fourth quarter 2007 adjusted EBITDA was $22.1 million, and the fourth quarter EBITDA margin was 4.5%, so we saw a nice improvement in both the EBITDA growth and margin growth quarter over quarter. Cash flow remained strong. We generated a solid $24 million in the fourth quarter of 2008 and $66 million for the year ended December 31, 2008.
Looking back over the year, a big takeaway from our first full year of operations is that we are seeing greater consistency in our financial results as we consolidate our pharmacies and streamline our operations. Fiscal 2008 adjusted EBITDA was $92.5 million compared to $67.9 million for fiscal 2007 on a combined basis.
We are also very proud that we’ve decreased our EBITDA leverage. The EBITDA leverage ratio has fallen from 3.1 times adjusted EBITDA at our inception to just under 2 times adjusted EBITDA at December 31, 2008. We are seeing major improvements not only in the income statement but also our balance sheet. As of today, we have completed all of our planned pharmacy consolidations. We still have about 15 legacy KPS locations to convert to our standard pharmacy operating platform, but we will move slowly on this. If it takes 2 or 3 years, that’s okay. Our focus in 2009 will be improving customer service, growing revenues, and building our acquisition program.